Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 8/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13818196 | 0.87 | KCNA3 (0.44) | KCNA3LMNAL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL4428524 | 0.86 | KCNA3 (0.58) | KCNA3CNR1 | |
| SCHEMBL3595473 | 0.85 | OPRM1 (0.47) | KCNA3LMNAL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL3900140 | 0.84 | KCNA3 (0.47) | KCNA3LMNAL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL3900137 | 0.84 | KCNA3 (0.47) | KCNA3LMNAL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL3908651 | 0.84 | KCNA3 (0.47) | KCNA3LMNAL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL3593944 | 0.81 | TACR1 (0.48) | KCNA3LMNAL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL21111717 | 0.81 | KCNA3 (0.64) | KCNA3LMNAL3MBTL1SMN1; SMN2NPSR1 | |
| SCHEMBL4437708 | 0.80 | KCNA3 (0.40) | KCNA3ALDH1A1 | |
| SCHEMBL4520783 | 0.80 | OPRM1 (0.42) | KCNA3LMNAL3MBTL1SMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3478662-B1 | AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO5) LTD (GB) | 2020-09-16 | — | — | EP | disclosed |
| US-20190209550-A1 | AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209550-A1 | AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | SAMHD1, AZI2, CDKN1A | KCNA3 4287/4885LMNA 3543/4885L3MBTL1 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.